Experience of 177Lu-PSMA-617-administration on Port Reservoir (TIVAP)

RecruitingOBSERVATIONAL
Enrollment

107

Participants

Timeline

Start Date

June 5, 2025

Primary Completion Date

June 19, 2025

Study Completion Date

July 30, 2025

Conditions
Administration of Therapy
Interventions
OTHER

to measure the residual activity on the Totally Implantable Venous Access Port

VOI (volume of interest)TIVAP at 4 ml were drawn manually on the chamber of the TIVAP on each tomography. Blood background was determined by an VOI (volume of intesrest of Right Auricle on the right atrium. The VOIRA was automatically delineated on the CT by XXX. Standardized Uptake Value (SUV)max, SUVpeak, SUVmean were extracted from the VOIs and unilateral comparisons of superiority were performed using Wilcoxon tests. A qualitative analysis along the (TIVAP) catheter was performed: positive if an uptake was superior to the blood background and negative if any.

Trial Locations (2)

54511

RECRUITING

CHRU de NANCY, Vandœuvre-lès-Nancy

RECRUITING

Nuclear medicine Department CHRU de NANCY, Vandœuvre-lès-Nancy

All Listed Sponsors
lead

Central Hospital, Nancy, France

OTHER

NCT06858995 - Experience of 177Lu-PSMA-617-administration on Port Reservoir (TIVAP) | Biotech Hunter | Biotech Hunter